Danaher Corp.

Danaher Corp.

DHR

Get informed when a big investor buys or sells

+ Follow
Market Cap$129.29B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Danaher Corp.Danaher Corp.35.10.74%7%5.10.3

Earnings Call Q1 2026

April 21, 2026 - AI Summary

Solid Q1 Performance and Guidance Increase: Danaher Corporation reported sales of $6 billion for Q1 2026, with a year-over-year core revenue growth of 0.5%. Adjusted diluted net earnings per share rose 9.5% to $2.06. The company raised its full-year adjusted EPS guidance to a range of $8.35 to $8.55, up from previous expectations of $8.35 to $8.50, indicating strong underlying operational execution.
Bioprocessing Strength: Bioprocessing demonstrated high single-digit growth, led by robust demand for commercialized therapies and positive order trends, with over 30% growth in equipment orders. This signals a potential shift towards a multiyear investment cycle, driven by anticipated capacity expansion in bioprocessing for biologic drug production.
Diversified Growth Across Segments: The company experienced better-than-expected growth in Life Sciences and strong performance from small biotechnology and academic customers. However, Diagnostics faced a 4% core revenue decline, primarily due to headwinds in the Chinese market caused by volume-based procurement and policy changes.

Exclusive for Stockcircle Pro members

Sign upSign Up
$225.80

Target Price by Analysts

26.8% upsideDanaher Target Price DetailsTarget Price
$185.86

Current Fair Value

4.4% upside

Undervalued by 4.4% based on the discounted cash flow analysis.

Share Statistics

Market cap$129.29 Billion
Enterprise Value$142.07 Billion
Dividend Yield$1.36 (0.74%)
Earnings per Share$5.07
Beta0.84
Outstanding Shares707,900,000

Return

Return on Equity6.97%ROE
Return on Assets4.42%
Return on Invested Capital6.14%

Valuation & Multiples

P/E Ratio35.05P/E Ratio
PEG445.88PEG
Price to Sales5.09Price to Sales
Price to Book Ratio2.41Price to Book Ratio
Enterprise Value to Revenue5.73
Enterprise Value to EBIT30.39
Enterprise Value to Net Income38
Total Debt to Enterprise0.13
Debt to Equity0.35Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
April 28, 2026
EPS Estimate
$1.94
Average shareholder expectation
Revenue Estimate
$6.00 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 28, 2026
EPS Estimate
$1.85
Average shareholder expectation
Revenue Estimate
$6.09 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.6768 17.65%
Total Calls3,311,815 25.17%
Total Puts2,241,515 40.64%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %80.69% 1.57%
Total Invested$108.09B 18.86%
Investors Holding2,211 159.00%

ESG Score

No data

About Danaher Corp.

2,020 employees
CEO: Rainer Blair

Relevant Senate Committees

Joint Committee on Taxation

While advisory, this committee's non-partisan analysis and 'revenue estimates' are crucial for the development and passage of all tax legislation. Its work directly influences corporate tax structures, capital investment credits, and the overall tax burden on companies like Danaher.

Finance

As a large, global corporation, Danaher is profoundly affected by this committee's decisions on taxation and trade policy (tariffs). These policies directly impact corporate valuations, profitability, and international business operations.

Appropriations

This committee directly allocates discretionary federal spending. Its subcommittees determine precise funding for scientific research, healthcare programs (e.g., NIH, VA), environmental agencies (EPA), and defense, all of which are significant customers or influence markets for Danaher's products.

Health, Education, Labor, and Pensions

Danaher's significant life sciences, diagnostics, and medical instrument businesses are directly impacted by regulations from the FDA and funding from the NIH, both overseen by this committee. Labor laws also broadly affect its operations.

Judiciary

Danaher is a large company active in mergers and acquisitions. This committee's oversight of antitrust laws and intellectual property (IP) is highly relevant, as M&A approvals and IP protection are critical for Danaher's growth strategy and competitive position.

Veterans' Affairs

Danaher manufactures medical instruments and diagnostic tools. This committee's funding decisions for the Department of Veterans Affairs directly impact government healthcare contractors and the demand for medical devices and diagnostics within the VA healthcare system.

Select Committee on Intelligence

Members receive classified briefings on global threats, including biosecurity and emerging health risks. Danaher's life sciences and diagnostics businesses are critical for responding to such threats, creating potential for significant informational asymmetry regarding future government needs or initiatives.

Environment and Public Works

Danaher's 'Environmental & Applied Solutions' segment directly benefits from and is impacted by regulations from the EPA. This committee's decisions on environmental policy and infrastructure drive demand for Danaher's measurement, monitoring, and control instruments.